MedTrace Logo

Extracellular RNA Biomarkers of Myotonic Dystrophy

NCT05020002 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 215

Last updated 2025-11-24

No results posted yet for this study

Summary

Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample.

Conditions

  • Myotonic Dystrophy

Sponsors & Collaborators

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • University of Texas

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Thurman M. Wheeler, MD · Massachusetts General Hospital

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-08
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020002 on ClinicalTrials.gov